Stockscreener 앱 받기
6.245
3.83%
0.245
전일 마감가:
$6.00
열려 있는:
$5.91
하루 거래량:
132.17K
Relative Volume:
0.67
시가총액:
$367.55M
수익:
$30.91M
순이익/손실:
$-74.28M
주가수익비율:
-5.126
EPS:
-1.2183
순현금흐름:
$-86.15M
1주 성능:
+24.35%
1개월 성능:
+67.92%
6개월 성능:
+19.12%
1년 성능:
+27.40%
1일 변동 폭
$5.84
$6.45
1주일 범위
$4.8301
$6.45
52주 변동 폭
$3.27
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
6.26 | 352.28M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
514.45 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
666.51 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
917.70 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.69 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.75 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2025-12-18 | 개시 | BTIG Research | Buy |
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
FHTXFoghorn Therapeutics Inc Options - Finviz
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.
Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings - Barchart.com
Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX) - TradingView
Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
FHTX Forecast — Price Target — Prediction for 2027 - TradingView
Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike - Stock Titan
Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares - Stock Titan
Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant - Stock Titan
Director Michael Mendelsohn gets 28,000 Foghorn (FHTX) stock options at $4.08 - Stock Titan
Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options - Stock Titan
Director Douglas G. Cole receives 28,000 Foghorn (NASDAQ: FHTX) stock options - Stock Titan
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters - The Globe and Mail
Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor - Stock Titan
Foghorn Therapeutics Inc. (FHTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics Inc. (FHTX) Institutional Confidence - TradingKey
Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Foghorn Therapeutics Inc. (FHTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Investing News Network
Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event - Stock Titan
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO) - The Globe and Mail
Foghorn Therapeutics to Present at Three Investor Conferences in May - geneonline.com
Foghorn Therapeutics (FHTX) Rises 1.44% as Biotech Stock Tests Key Resistance at $4.43MESA MA - newsline.com
Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan
EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov
[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News
Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network
Biotech Foghorn lines up three May oncology investor events - Stock Titan
Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
5.65%
자본화:
|
볼륨(24시간):